TALK Quote, Financials, Valuation and Earnings

Pediatrix Medical Group has a net margin of 0.61% compared to Talkspace's net margin of 4.52%. Talkspace's return on equity of 2.52% beat Pediatrix Medical Group's return on equity of -10.7%.

Talkspace has a consensus price target of $4.88, signalling upside risk potential of 61.42%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.50 which suggests that it could grow by 20.44%. Given that Talkspace has higher upside potential than Pediatrix Medical Group, analysts believe Talkspace is more attractive than Pediatrix Medical Group.

Talkspace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.315%.

Talkspace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talkspace pays -- of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

Talkspace quarterly revenues are $52.2M, which are smaller than Pediatrix Medical Group quarterly revenues of $458.4M. Talkspace's net income of $318K is lower than Pediatrix Medical Group's net income of $20.7M. Notably, Talkspace's price-to-earnings ratio is 175.60x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talkspace is 2.79x versus 0.62x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

ModivCare has a net margin of 0.61% compared to Talkspace's net margin of -3.34%. Talkspace's return on equity of 2.52% beat ModivCare's return on equity of -408.97%.

Talkspace has a consensus price target of $4.88, signalling upside risk potential of 61.42%. On the other hand ModivCare has an analysts' consensus of $6.75 which suggests that it could grow by 476.92%. Given that ModivCare has higher upside potential than Talkspace, analysts believe ModivCare is more attractive than Talkspace.

Talkspace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ModivCare has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.86%.

Talkspace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ModivCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talkspace pays -- of its earnings as a dividend. ModivCare pays out -- of its earnings as a dividend.

Talkspace quarterly revenues are $52.2M, which are smaller than ModivCare quarterly revenues of $702.8M. Talkspace's net income of $318K is higher than ModivCare's net income of -$23.5M. Notably, Talkspace's price-to-earnings ratio is 175.60x while ModivCare's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talkspace is 2.79x versus 0.01x for ModivCare. Usually stocks with elevated PS ratios are considered overvalued.

Marpai has a net margin of 0.61% compared to Talkspace's net margin of -58.85%. Talkspace's return on equity of 2.52% beat Marpai's return on equity of --.

Talkspace has a consensus price target of $4.88, signalling upside risk potential of 61.42%. On the other hand Marpai has an analysts' consensus of -- which suggests that it could fall by --. Given that Talkspace has higher upside potential than Marpai, analysts believe Talkspace is more attractive than Marpai.

Talkspace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Marpai has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Talkspace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marpai offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talkspace pays -- of its earnings as a dividend. Marpai pays out -- of its earnings as a dividend.

Talkspace quarterly revenues are $52.2M, which are larger than Marpai quarterly revenues of $7.4M. Talkspace's net income of $318K is higher than Marpai's net income of -$4.3M. Notably, Talkspace's price-to-earnings ratio is 175.60x while Marpai's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talkspace is 2.79x versus 0.30x for Marpai. Usually stocks with elevated PS ratios are considered overvalued.

Teladoc Health has a net margin of 0.61% compared to Talkspace's net margin of -14.78%. Talkspace's return on equity of 2.52% beat Teladoc Health's return on equity of -61.6%.

Talkspace has a consensus price target of $4.88, signalling upside risk potential of 61.42%. On the other hand Teladoc Health has an analysts' consensus of $9.18 which suggests that it could grow by 29.17%. Given that Talkspace has higher upside potential than Teladoc Health, analysts believe Talkspace is more attractive than Teladoc Health.

Talkspace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Teladoc Health has a beta of 1.824, suggesting its more volatile than the S&P 500 by 82.363%.

Talkspace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teladoc Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talkspace pays -- of its earnings as a dividend. Teladoc Health pays out -- of its earnings as a dividend.

Talkspace quarterly revenues are $52.2M, which are smaller than Teladoc Health quarterly revenues of $629.4M. Talkspace's net income of $318K is higher than Teladoc Health's net income of -$93M. Notably, Talkspace's price-to-earnings ratio is 175.60x while Teladoc Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talkspace is 2.79x versus 0.48x for Teladoc Health. Usually stocks with elevated PS ratios are considered overvalued.